ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
Rhea-AI Summary
ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and investor conferences in September 2026 in New York, including events hosted by Cantor, Moody Capital, H.C. Wainwright and Roth, plus a World Alzheimer’s Day appearance at the Nasdaq Tower on September 21.
Company executives Neil Warma (President & CEO), Dr. Larry Altstiel (CMO) and Carie Pierce (VP, Investor Relations & External Affairs) will discuss the EpiSelect™ platform, ProMIS’ approach to targeting toxic misfolded proteins in neurodegenerative diseases, and PMN310, its lead asset in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease. ProMIS recently reported blinded 6‑month interim data from this fully enrolled trial, with 12‑month topline data expected in early 2027. Webcast links and replays will be available via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | 2Q26 earnings report | Neutral | +0.2% | Quarterly results included clinical updates, cash runway, and a reported net loss. |
| Aug 03 | Earnings date notice | Neutral | -4.0% | The company scheduled its second-quarter results and business update for August 13. |
| Jul 28 | Phase 1b clinical data | Positive | +23.9% | Six-month blinded safety and biomarker data reported no ARIA-E cases. |
| Jul 27 | Phase 1b data webinar | Neutral | +23.9% | The company announced a webinar covering upcoming interim trial data. |
| Jul 14 | Clinical data update | Positive | +6.7% | Human data showed dose-dependent amyloid-beta oligomer reductions after PMN310 dosing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical updates aligned with positive reactions, while the prior earnings-date announcement diverged with a negative reaction.
Key Terms
misfolded proteins medical
phase 1b medical
blinded interim data medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
Conference details below:
September 9-11: Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET
Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief Executive Officer
Webcast link: Click Here
September 9-10: Moody Capital Disruptive Growth & Life Sciences Conference
Location: New York, NY
Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1
Webcast link: Click Here
September 14-16: H.C. Wainwright 28th Annual Global Investment Conference
Location: New York, NY
Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4th floor)
Webcast link: Click Here
September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower
Location: Nasdaq Tower, New York, NY
September 29: Roth Healthcare Opportunities Conference
Location: New York, NY
During these conferences, Neil Warma, President & Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations & External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.
ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.
Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website. Click Here
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact:
Carie Pierce, VP, Investor Relations & External Affairs
IR@promisneurosciences.com
